Taplitumomab paptox

Taplitumomab paptox is a monoclonal antibody that was developed for the treatment of cancer. It is also known by its developmental code name, B43.13.

History

Taplitumomab paptox was developed by the Immunogen Inc., a biotechnology company specializing in antibody-drug conjugates for the treatment of cancer. The drug was designed to target the CD22 antigen, a protein found on the surface of B cells, which are often involved in certain types of lymphoma and leukemia.

Mechanism of Action

Taplitumomab paptox is a monoclonal antibody conjugated to a toxin, hence the "paptox" in its name. The antibody portion of the drug binds to the CD22 antigen on the surface of B cells. Once bound, the drug is internalized by the cell, where the toxin is released. The toxin then interferes with protein synthesis, leading to cell death.

Clinical Trials

Taplitumomab paptox underwent Phase I and II clinical trials for the treatment of non-Hodgkin's lymphoma and B-cell acute lymphoblastic leukemia. However, the drug did not progress to Phase III trials, and its development was discontinued.

See Also

• Monoclonal antibodies
• Antibody-drug conjugate
• CD22
• Non-Hodgkin's lymphoma
• B-cell acute lymphoblastic leukemia

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian